# **Product** Data Sheet

## **BAY-0069**

Cat. No.: HY-148351 CAS No.: 420826-65-9 Molecular Formula:  $C_{22}H_{16}BrN_3O_4$ Molecular Weight: 466.28

**PPAR** Target:

Pathway: Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor

Storage: Powder -20°C 3 years

In solvent -80°C 6 months

-20°C 1 month

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (214.46 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1446 mL	10.7232 mL	21.4463 mL
	5 mM	0.4289 mL	2.1446 mL	4.2893 mL
	10 mM	0.2145 mL	1.0723 mL	2.1446 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

Description BAY-0069 is a potent and selective PPARγ inverse agonist with an IC<sub>50</sub> value of 6.3 nM and 24 nM for human PPARγ and

mouse PPARy. BAY-0069 can be used to research cancer[1].

IC<sub>50</sub> & Target hPPARγ mouse PPARγ

> 6.3 nM (IC<sub>50</sub>) 24 nM (IC<sub>50</sub>)

BAY-0069 inhibits CYP2C8 with an IC<sub>50</sub> of 4.3  $\mu$ M<sup>[1]</sup>. In Vitro

BAY-0069 (0.1 nM-1  $\mu$ M; 7 days) leads to antiproliferative effects in the PPAR $\gamma$ -amplified cell line UM-UC-9<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line:	PPARγ-amplified cell line UM-UC-9
Concentration:	0.0001, 0.001, 0.01, 0.01 and 1 $\mu M$
Incubation Time:	7 days

	Result:	Inhibited PPARγ-amplified cell line UM-UC-9 with an IC <sub>50</sub> of 2.54 nM.				
In Vivo	BAY-0069 (1 $\mu$ M; 1 h) exhibits excellent microsomal stability with CL <sub>b,hmic</sub> of 0.47 L/h/kg in human liver microsomes and CL b,rhep of 3.9 L/h/kg in rat liver hepatocytes <sup>[1]</sup> . Pharmacokinetic Parameters of BAY-0069 in female NMRI nu/nu mice <sup>[1]</sup> .					
	Route	P.O. (100 mg/kg)	I.P.	S.C.		
	AUC <sub>0-tlast</sub> (mg/L·h)	0.074	0.26	0.045		
	C <sub>max</sub> (nM)	35	59	4.4		
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.					

### REFERENCES

[1]. Orsi DL, Goldstein JT, et al. Discovery and Structure-Based Design of Potent Covalent PPARy Inverse-Agonists BAY-4931 and BAY-0069. J Med Chem. 2022 Nov 10;65(21):14843-14863.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA